Tae Hata

Tae Hata

Auto-generated profile, based on publicly available information

Tae Hata

Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
SGShiho Goda
Shiho Goda
TYTadaaki Yamada
Tadaaki Yamada
KMKenji Morimoto
Kenji Morimoto
THTae Hata
Tae Hata
YGYasuhiro Goto
Yasuhiro Goto
KTKoichi Takayama
Koichi Takayama
Original Article Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan Shiho Goda, Tadaaki Yamada, Kenji Morimoto, Tae Hata, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Satoshi Watanabe, Naoki Furuya, Tomohiro Oba, Tatsuki Ikoma, Akira Nakao, Keiko Tanimura, Hirokazu Taniguchi, Akihiro Yoshimura, Tomoya Fukui, Daiki Murata, Kyoichi Kaira, Shinsuke Shiotsu, Asuka Okada, Makoto Hibino, Yusuke Chihara, Takashi Kijima, Koichi Takayama

3 March 2023 in Thoracic Cancer
Verified
Journal Article
Open access
THTae Hata
Tae Hata
CSChikara Sakaguchi
Chikara Sakaguchi
KHKeita Hirano
Keita Hirano
HKHiroshi Kobe
Hiroshi Kobe
MIMasaki Ishida
Masaki Ishida
YNYukio Nagasaka
Yukio Nagasaka
Background: Patients with epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer have received immunochemotherapy as one of the treatment options after tyrosine kinase inhibitor (TKI) failure.Methods: We retrospectively examined EGFR-mutant patients treated with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) therapy or platinum-based chemotherapy (Chemo) after EGFR-TKI therapy at five institutions in Japan.Results: A total of 57 patients with EGFR mutation were analyzed. The median progression-free survival (PFS) and overall survival (OS) in the ABCP (n = 20) and Chemo (n = 37) were 5.6 and 20.9 months, 5.4 and 22.1 months, respectively (PFS, p = 0.39; OS, p = 0.61). In programmed death-ligand 1 (PD-L1)-positive patients, median PFS in the ABCP group was longer than in the Chemo group (6.9 vs. 4.7 months, p = 0.89). In PD-L1-negative patients, median PFS in the ABCP group was significantly shorter than in the Chemo group (4.6 vs. 8.7 months, p = 0.04). There was no difference in median PFS between the ABCP and Chemo groups in the subgroups of brain metastases, EGFR mutation status, or chemotherapy regimens, respectively.Conclusion: The effect of ABCP therapy and chemotherapy was comparable in EGFR-mutant patients in a real-world setting. The indication for immunochemotherapy should be carefully considered, especially in PD-L1-negative patients.

1 July 2025 in Cancer Research Communications
Verified
Journal Article
Open access
THTae Hata
Tae Hata
TYTadaaki Yamada
Tadaaki Yamada
YGYasuhiro Goto
Yasuhiro Goto
AAAkihiko Amano
Akihiko Amano
YNYoshiki Negi
Yoshiki Negi
KTKoichi Takayama
Koichi Takayama
Chemoimmunotherapy is recommended for patients with non–small cell lung cancer (NSCLC) with low PD-L1 expression, but the effect of additional immunotherapy is heterogeneous in this population. To identify patients who do not benefit from the addition of immune checkpoint inhibitors (ICI) to chemotherapy, we conducted a retrospective study at 19 institutions in Japan. We analyzed 851 patients with advanced NSCLC with a PD-L1 tumor proportion score of 1% to 49% who received chemoimmunotherapy (n = 504) or chemotherapy (n = 347) between March 2017 and June 2022. After adjustment by propensity score matching, the median overall survival (OS) was 22.3 months in the chemoimmunotherapy group and 17.0 months in the chemotherapy-alone group (P = 0.01). Multivariate analysis showed that among 12 clinical factors, liver metastases (P = 0.001) and history of antibiotic use (P = 0.02) were independently associated with shorter OS in the chemoimmunotherapy group. Patients with liver metastases (OS, P = 0.4; progression-free survival, P = 0.06) or history of antimicrobial use (OS, P = 0.24; progression-free survival, P = 0.09) did not benefit from the addition of ICI to chemotherapy. Patients with a history of antimicrobial use experienced more severe pneumonitis with chemoimmunotherapy than all patients (P = 0.04). This cohort study showed that liver metastases and prior antimicrobial therapy are the most important clinical factors that attenuate the efficacy of chemoimmunotherapy in patients with low PD-L1 expression. Significance: This study shows that liver metastases and prior antibiotic use are key factors for chemoimmunotherapy in advanced NSCLC cases with low PD-L1 expression. They reduce the benefit of adding ICIs to chemotherapy, underscoring the need for new strategies to improve ICI efficacy in patients.

23 June 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
THTae Hata
Tae Hata
CSChikara Sakaguchi
Chikara Sakaguchi
KHKeita Hirano
Keita Hirano
HKHiroshi Kobe
Hiroshi Kobe
MIMasaki Ishida
Masaki Ishida
YNYukio Nagasaka
Yukio Nagasaka

19 November 2025 in Lung Cancer
Verified
Journal Article
Closed access
MIMasaki Ishida
Masaki Ishida
TYTadaaki Yamada
Tadaaki Yamada
RTRyo Tsunashima
Ryo Tsunashima
MMMidori Morita
Midori Morita
NKNobutaka Kataoka
Nobutaka Kataoka
KTKoichi Takayama
Koichi Takayama